Extreme weakness associated with gastric adenocarcinoma: Beyond the expected;Debilidad extrema asociada a adenocarcinoma gástrico: Más allá de lo esperado

Revista Clinica Espanola

Volumn 203, Issue 3, 2003, Pages 157-158

  Perez Paredes M G ^a   Martin Escudero J C ^a   Perez Castrillon J L ^a   Herreros Fernandez V ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHYLPREDNISOLONE; PYRIDOSTIGMINE;

AGED; ARTICLE; CASE REPORT; CHOLINERGIC TRANSMISSION; CLINICAL FEATURE; COMORBIDITY; EATON LAMBERT SYNDROME; ELECTROMYOGRAPHY; GASTROSCOPY; HUMAN; LABORATORY TEST; MUSCLE WEAKNESS; NEUROMUSCULAR TRANSMISSION; PARANEOPLASTIC SYNDROME; PHYSICAL EXAMINATION; PLASMAPHERESIS; STOMACH ADENOCARCINOMA; SYMPTOMATOLOGY;

EID: 0344088992     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13044928     Document Type: Article

References (6)

1. Levin KH. Paraneoplastic neuromuscular syndromes. Neurologic Clinics 1997;15:3.
2. Sánchez Novials A, Sabria M, Cabre J, Jane C, Villegas G, Rey-Joli Barroso C. Síndrome de Eaton-Lambert. A propósito de cuatro observaciones. Rev Clin Española 1982;164:4.
3. Yuste Ara JR, Beloqui Ruiz O, Artieda González-Granda J, Herrero Santos JI, de la Peña Fernández A, Prieto Valtueña J. Ciclosporina-A como tratamiento del síndrome miasteniforme de Eaton-Lambert. Ann Med Intern 1996;13:25-6.
4. Seneviratne U, de Silva R. Lambert-Eaton myasthenic syndrome. Postgrad Med J 1999;75:516-20.
5. Rooke ED, Eaton LM, Lambert EH, Hodgson CH. Myasthenia and malignant intrathoracic tumor. Med Clin North Am 1960;44:977-88.
6. Collins DR, Connolly S, Burns M, Offiah L, Grainger R, Walsh JB. Lambert-Eaton myasthenic syndrome in association with transitional sell carcinoma: a previously unrecognized association. Urology 1999; 54:162.